Promega and Henlius Developing Microsatellite Instability Companion Diagnostic IVD Kit for Serplulimab in China

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors.